Based on our comparison of MSVA-708R and MRQ-50, we assume that very high positivity rates in many tumor entities that were largely PAX8 negative in our cohort were driven by similar antibody-specific cross-reactivities. The gene discussed is PAX8; the disease is neoplasm.